About Molecure S.A.

Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate underexplored protein targets and the function of RNA to treat multiple incurable diseases.

Our extensive in-house expertise has allowed us to collaborate with top global academic research institutes to access untapped, novel biology targets.

We have generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally, including Yale University, Rutgers University, the Flemish Institute for Biotechnology (VIB) in Ghent, the University of Michigan and the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), which has significant expertise in RNA science and technology.

Our most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready. A Phase II trial in patients with sarcoidosis is expected to start in 2023.

Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, which is at the stage of Phase I clinical development.

About Molecure S.A.

Meet us

Our Leadership

Our team brings together exceptional capabilities in medicinal chemistry and translational science combined with an experienced entrepreneurial management team that are passionate about exploring the unexplored.

Management Board

Marcin Jan Szumowski

PRESIDENT OF THE BOARD,
CHIEF EXECUTIVE OFFICER

Sławomir Piotr Broniarek

MEMBER OF THE BOARD,
CHIEF FINANCIAL OFFICER

Zbigniew Zasłona

MEMBER OF THE BOARD,
CHIEF SCIENTIFIC OFFICER

Agnieszka Rajczuk-Szczepańska

MEMBER OF THE BOARD,
HR DIRECTOR

Samson Fung

MEMBER OF THE BOARD
CHIEF MEDICAL OFFICER

Supervisory Board

Paul Van der Horst, PhD

PRESIDENT OF THE SUPERVISORY BOARD

Tomasz Piec

VICE-CHAIRMAN OF THE SUPERVISORY BOARD

Agnieszka Motyl, MD, PhD

MEMBER OF THE SUPERVISORY BOARD

Nancy Van Osselaer, PhD

MEMBER OF THE SUPERVISORY BOARD

Paweł Trawkowski

MEMBER OF THE SUPERVISORY BOARD

Management Team

Jacek Olczak

HEAD OF MEDICINAL CHEMISTRY

Adam Gołębiowski

SENIOR RESEARCH FELLOW

Marta Dudek

MEDICAL DIRECTOR

Marta Borkowska

DIRECTOR OF THE MANAGEMENT BOARD OFFICE

Scientific Advisory Board

Bart Lambrecht

MD, PhD

Nancy Van Osselaer

PhD

Reynold A. Panettieri Jr.

MD, PhD

Douglas Hay

PhD

Rafał Krenke

MD, PhD

Luke O’Neill

PhD

This site is registered on wpml.org as a development site.